Abstract
With the increasing application of immune checkpoint inhibitors (ICIs) in tumor immunotherapy, the side effects on the immune system, known as immune-related adverse reactions (irAEs), also pose a key challenge to the clinical use of ICIs. Prior to this study, there was yet to be a comprehensive and systematic analysis of the relationship between ICIs, psychiatric complications and their influencing factors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
